Blackett, N M Courtenay, V D Mayer, S M
Published in
Cancer chemotherapy reports. Part 1
A comparison has been made of the effects of three nitrosoureas (BCNU, CCNU, and methyl-CCNU) on the cells of Lewis lung carcinoma and B16 melanoma in vivo using a new in vitro method for assaying colony-forming cells. In addition, the effect on early hemopoietic precursors has been studied using the in vivo spleen colony assay and the in vitro aga...
Published in
Cancer chemotherapy reports. Part 1
Skovsgaard, T
Published in
Cancer chemotherapy reports. Part 1
Resistance to a new daunorubicin derivative, rubidazone, was developed in a strain of Ehrlich ascites tumor in vivo by treatment with the drug during 11 weekly passages of the tumor. In this tumor reciprocal cross resistance was found between rubidazone, daunorubicin, adriamycin, vincristine, and vinblastine. There was no change in sensitivity of t...
Horton, J Mittelman, A Taylor, S G 3rd Jurkowitz, L Bennett, J M Ezdinli, E Colsky, J Hanley, J A
Published in
Cancer chemotherapy reports. Part 1
One hundred and ninety-seven patients with measurable metastatic cancer of the colon have been treated with one of four anticancer drugs which have had little prior trial in this disease. Objective tumor responses lasting a median of 9 weeks occurred with 0.5 g/m of streptozotocin given intravenously every week (10 percent), 130 mg/m of CCNU given ...
Davidson, J P Faber, P J Fischer, R G Jr Mansy, S Peresie, H J Rosenberg, B VanCamp, L
Published in
Cancer chemotherapy reports. Part 1
The diaquo species of cis-dichlorodiammineplatinum (II) reacts with pyrimidines and substituted pyrimidines to form very soluble, deep blue complexes. These are believed to consist of mainly monomeric species containing one pyrimidine moiety liganded to each platinum. The structures of the complexes are largely uncertain at this time. We describe t...
McInnis, B Kapadia, A El-Asfouri, S Loo, T L
Published in
Cancer chemotherapy reports. Part 1
Odujinrin, O O DeConti, R C Bertino, J R
Published in
Cancer chemotherapy reports. Part 1
Forty patients with advanced solid tumors of diverse primary sites received a combination of cyclophosphamide (1 gm/m2), cytosine arabinoside (300 mg/m2), and methotrexate (80 mg/m2) given intermittently at 2-3-week intervals. Eight of the 40 patients received citrovorum factor rescue. The major limitation of therapy was suppression of bone marrow ...
Hadd, H E
Published in
Cancer chemotherapy reports. Part 1
Schecter, J P Jones, S E Jackson, R A
Published in
Cancer chemotherapy reports. Part 1
Cohen, M H Creaven, P J Tejada, F Hansen, H H Muggia, F Mittelman, A Selawry, O S
Published in
Cancer chemotherapy reports. Part 1
An initial clinical phase I trial of isophosphamide has been carried out at dose levels of 200-10,000 mg/m2 of body surface area using a single-dose, every-3-week schedule. Significant toxicity was not seen at isophosphamide dose levels less than 2900 mg/m2. At higher doses, nausea and vomiting was nearly universal. Hematologic toxicity manifested ...
